Marketed in 43 countries across Europe, North America, and Oceania, Revatio is a globally distributed brand of sildenafil, a medication classified within the PDE-5 inhibitor pharmacological category. Although sildenafil is most widely recognised under a different brand for a different indication, Revatio represents the same molecule positioned specifically for cardiopulmonary use, and this page is aimed at travellers, expatriates, and family members trying to identify the medication abroad.
Revatio is prescribed in the management of pulmonary arterial hypertension and related pulmonary hypertension presentations, and the structured indication section further down this page reflects the registered uses recognised in the markets where the brand is sold, including references to associated cardiac and congenital heart disease contexts. It belongs to a therapeutic area where consistent access to medication matters across borders, which is one reason its international footprint is relatively broad.
Because Revatio is registered in such a wide range of markets — including Germany, Canada, Australia, France, and the Czech Republic — travellers frequently encounter it abroad, sometimes under the Revatio brand and sometimes as a sildenafil-containing generic intended for the same indication. Regulatory packaging, prescription pathways, and even the visual presentation of the tablet can differ meaningfully from one country to another, and a local pharmacist is usually the most efficient point of contact for confirming whether what is on a local shelf corresponds to what was originally prescribed.
Other medications within the PDE-5 inhibitor class are sold in many of the same markets under different molecules and brand names, although they are not freely interchangeable. Patients managing pulmonary hypertension should treat any change of brand, generic, or molecule as a clinical decision: a healthcare provider familiar with the individual case is the appropriate person to authorise it, and a pharmacist can help identify the available regional options.
Revatio is used in the management of pulmonary arterial hypertension and related forms of pulmonary hypertension, including presentations associated with underlying heart disease and congenital heart disease. As a PDE-5 inhibitor, it occupies a defined role within the cardiopulmonary therapeutic category. The structured indication block below this introduction reflects the full registered indications recognised in the markets where Revatio is authorised.
Revatio contains sildenafil, a PDE-5 inhibitor. The same molecule circulates internationally under several brand names, and sildenafil is also marketed for an unrelated indication under a separate, well-known brand — the Revatio presentation specifically positions the ingredient for pulmonary hypertension. Generic sildenafil products intended for this indication are also available in a number of regulated markets.
Revatio is registered in 43 countries, with strong representation across Europe, North America, and Oceania. Examples include Australia, Canada, Germany, France, Finland, Greece, and the Czech Republic. If your country is not represented in the structured list below, a local pharmacist can usually confirm whether sildenafil is available locally for pulmonary hypertension under another brand name or as a generic.
Sildenafil is sold under several brand names worldwide, including generic sildenafil products specifically authorised for pulmonary hypertension in markets where the original patent has expired. Other medications within the broader PDE-5 inhibitor class also exist, although they are not freely interchangeable, and additional drug classes are used in pulmonary hypertension management. To identify a local equivalent, search the active ingredient on Pill2Trip or consult a pharmacist.
Yes. Revatio is a prescription medication, and pulmonary hypertension therapy is highly individualised, calibrated to the patient's underlying cardiopulmonary status and concurrent treatments. This matters particularly for travellers and people relocating between countries, since prescription rules, available brands, and generic options vary by jurisdiction. Any decision to start, stop, switch, or substitute sildenafil for this indication should be led by a healthcare provider familiar with the case.
